	US 12,404,332 B2
	Methods for diagnosing and treating cancers
Tyler J. Curiel, San Antonio, TX (US); and Anand Kornepati, San Antonio, TX (US)
Assigned to Research Development Foundation, Carson City, NV (US)
Filed by Research Development Foundation, Carson City, NV (US)
Filed on Mar. 12, 2021, as Appl. No. 17/200,729.
Claims priority of provisional application 63/000,187, filed on Mar. 26, 2020.
Claims priority of provisional application 62/989,164, filed on Mar. 13, 2020.
Prior Publication US 2021/0332136 A1, Oct. 28, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 31/196 (2006.01); A61K 31/437 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 31/675 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); G01N 33/68 (2006.01)

CPC C07K 16/2827 (2013.01) [A61K 31/196 (2013.01); A61K 31/437 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/675 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); G01N 33/68 (2013.01); A61K 2039/505 (2013.01); G01N 2333/4703 (2013.01); G01N 2800/7028 (2013.01)]

48 Claims

1. A method of treating a melanoma, bladder, breast or ovarian cancer in a human subject, comprising measuring in cells of the melanoma, bladder, breast or ovarian cancer the expression of

i) cytoplasmic or intracellular PD-L1 and/or

ii) one or more Lamtor proteins; and

administering an anti-cancer therapy to the subject having the melanoma, bladder, breast or ovarian cancer, wherein the cancer expresses cytoplasmic or intracellular PD-L1 and/or one or more LAMTOR proteins at a decreased level as compared to such expression in control cells; wherein:

i) when the cancer is melanoma the control cells are B16 cells;

ii) when the cancer is bladder cancer the control cells are RT4 cells;

iii) when the cancer is breast cancer control cells are 4TI cells; and

iv) when the cancer is ovarian cancer and wherein the control cells are ES2 cells.